CHICAGO — Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which may help establish it as the new standard treatment for the condition.
The drug, called Lorbrena, also cut the risk of the cancer progressing in patients' brains.
Only about 5% of all non-small cell lung cancer patients have the mutation, which causes cancer cells to grow and spread abnormally.
But Pfizer's drug isn't currently considered the standard – or the most appropriate and widely used – treatment for the condition.
Nearly 300 people in the trial either received Lorbrena or Pfizer's older lung cancer drug Xalkori.
Persons:
isn't, Chris Boshoff, Lorbrena, David Spigel, Sarah Cannon, Spigel, Andrew Berens, Pfizer's Boshoff
Organizations:
CHICAGO, Pfizer, CNBC, Lorbrena's, American Society of Clinical Oncology, Clinical Oncology, Sarah, Sarah Cannon Research Institute, Lorbrena, Leerink
Locations:
U.S, Chicago